Development of inhibitors in patients with haemophilia from India

Haemophilia

Volumn 7, Issue 3, 2001, Pages 273-278

  Ghosh, K ^a   Shetty, S ^a   Kulkarni, B ^a   Nair, S ^a   Pawar, A ^a   Khare, A ^a   Baindur, S ^a   Mohanty, D ^a  

^a KEM HOSPITAL   (India)

Author keywords

Familial inhibitor; Haemophilia; Inhibitors; Intron 22; Inversion; Persistence

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING INHIBITOR; FRESH FROZEN PLASMA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CHROMOSOME INVERSION; CRYOPRECIPITATE; DISEASE SEVERITY; EXPOSURE; FAMILY; FOLLOW UP; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INDIA; INTRON; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; SAMPLE; SCREENING; SYMPTOM; TIME; WESTERN HEMISPHERE;

ADOLESCENT; ADULT; CHILD; FACTOR IX; FACTOR VIII; FAMILY HEALTH; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INDIA; INTRONS; INVERSION, CHROMOSOME; ISOANTIBODIES; MIDDLE AGED; PREVALENCE; TIME FACTORS;

EID: 0035018007     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00505.x     Document Type: Article

References (30)

1. Scharrer I, Nentlzing O. Incidence of inhibitors in haemophiliacs. A review of literature. Blood Coag Fibrinol 1993; 4: 753-8.
2. Brettler D. Inhibitor of factor VIII and IX. Haemophilia 1995; 1 (Suppl. 1): 35-9.
3. Addiego J, Casper CK, Abildgaard C et al. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993; 342: 462-4.
4. Hoyer LW. Why do so many haemophilia A patients develop inhibitors? Br J Haematol 1995; 90: 498-501.
5. Vermylen J. How do some haemophiliacs develop inhibitors? Haemophilia 1988; 4 (4): 538-42.
6. Peerlinick K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young haemophilia A patients treated exclusively with lyophilised cryoprecipitate. Blood 1993; 81: 3332-5.
7. Oldenberg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EGD, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors to factor VII. Thromb Haemost 1997; 77: 238-42.
8. Brezovic M, Mackie I. Investigation of a bleeding tendency. In: Dacie V, Lewis SM, eds. Practical Haematology London: Churchill Livingstone UK. 1991: 293-318.
9. Verbruggen B, Novakova I, Wessels H, Boezsman J, Vanden Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
10. Shetty S, Pathare A, Ghosh K, Jijina F, Mohanty D. Intron 22 inversions in factor VIII gene in Indian haemophiliacs. Thromb Haemost 1998; 79: 881.
11. Sultan Y, the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 haemophilia patients in France. Thromb Haemost 1992; 67: 600-2.
12. McMillan CW, Shepiro SS, Whithust D et al. The natural history of factor VIII: C inhibitor in patients with hemophilia A. A National Cooperative study: observations on the initial development of factor VHI:C inhibitor. Blood 1988; 71: 344-8.
13. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Sohapiro A, Scheibel E, White IIG, Lee M, Recombinate Study Group. A multicentre study of recombinant factor VIII (Recombinate): Safety, efficacy and inhibitor risk in previously untreated patients with haemophilia A. Blood 1994; 83: 2428-35.
14. Lusher JM. Human antibodies to recombinant factor VIII in haemophiliacs. J Interferon Res 1994; 14:173-4.
15. Hoyer LW, Aledort LM, Hoyer LW, et al. The incidence of factor VIII inhibitors in patients with severe haemophilia A. In: Inhibitors to Coagulation Factors New York: Plenum Press. 1995: 35-43.
16. Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost 1997; 78: 1027-9.
17. Ghosh K, Joshi SH, Shetty S et al. Transfusion transmitted diseases in haemophiliacs from western India. Indian J Med Res 2000; 112: 61-4.
18. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
19. Shetty S, Ghosh K, Pathare AV, Mohanty D. Clinically significant inhibitors in haemophilia A patient from India tend to persist. Acta Haematol 2000; 103: 175-6.
20. Pathare AV, Ghamande S, Fernandes S et al. Acquired inhibitor to factor VIII. Report of two unusual cases. Haemophilia 1997; 3: 212-4.
21. Ghosh K, Jijina F, Pathare AV, Mohanty D. Surgery in haemophilia: Experience from a centre in India. Haemophilia 1998; 4: 94-7.
22. Bhusan V, Chandy M, Khanduri U, Dennison D, Shrivastava A. Surgery in patients with congenital coagulation disorders. Nat Med J Ind 1994; 7: 8-12.
23. Vermylen J, Peerlnick K. Epidemic of factor VIII inhibitors linked to factor VIH. P Acta Clin Belg 1991; 46:419.
24. Peerlnick K, Arnout J, Di Giambaltista M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
25. Ghosh K, Shetty S, Pathare A, Mohanty D. Epsilon aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe hemophilia in vivo and in vitro. Acta Haematol, in press.
26. Amano K, Arai M, Koshihara K et al. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex. Am J Haematol 1995; 49: 310-7.
27. Tizzano EF, Altisent C, Domenech M, Cornet M, Tusell J, Baiget M. Inhibitor development in haemophilia A patients with inversion of the intron 22 of the factor VIH gene. Thromb Haemost 1996; 76: 125-6.
28. Schwaab R, Brackmann HH, Meyer C et al. Mutation type determines the risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
29. Tuddenham EGD, Mcvey JH. The genetic basis of inhibitor development in haemophilia A. Haemophilia 1998; 4: 543-5.
30. Lusher JM. Hemophilia A and B. In: Lilleyman J, Hann I, Blanchette V, eds. Pediatric Hematology London: Churchill Livingstone UK. 1999: 585-600.